9:00 AM SIGN-IN • 9:30 AM - 11:00 AM

BANDOL 1 (NEW WYNN SPACE)

CE: Wet Age-Related Macular Degeneration: Examining Clinical and Economic Data

Neovascular or wet age-related macular degeneration (AMD) accounts for 10% to 15% of all cases of AMD. Wet AMD is responsible for about 90% of the loss of severe visual acuity due to accumulation of retinal fluid. Improved imaging technologies and home monitoring systems are transforming the management and diagnosis of patients with wet AMD. However, data indicate that wet AMD may still be underdiagnosed in the United States, and treatment delays can considerably contribute to economic burden for patients, caregivers, and the health care system. Approved and emerging treatment options with anti-vascular endothelial growth factor (VEGF) biologics offer individualized regimens for patients with wet AMD. Specialty pharmacists are well positioned to engage with managed care professionals and payers on the value of best practices to reduce the associated treatment burden of this disease. This session will explore extended dosing schedules of anti-VEGF biologics as well as the pharmacist’s role in promoting strategies for early and aggressive treatment to improve outcomes for patients with wet AMD.

Speakers

Jeffrey Dunn

Roger Goldberg

Asembia

200 Park Avenue, Suite 300 
Florham Park, NJ 07932

973.564.8004

asembia.com

info@asembiasummit.com

SIGN UP FOR SUMMIT UPDATES

Asembia's Specialty Pharmacy Summit is a PRIVATE EVENT. Asembia reserves the right to deny registration and refuse access at our absolute and sole discretion for any reason whatsoever.

© 2020 Asembia Specialty Pharmacy Summit, LLC. All rights reserved.

CONNECT WITH US

  • Asembia LinkedIn
  • Asembia Twitter
  • Asembia Instagram
  • Asembia Facebook
  • Asembia Videos
  • Asembia Photos
2021Summit_Logo_White.png